Xie, Shaozhen

CDK4/6 inhibition triggers anti-tumour immunity

Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature

Cancer Immunotherapy and BiomarkersAdvanced Breast Cancer Therapies

Cited by 1,513

PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer

Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports

PARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers

Cited by 572

Induction of Androgen Receptor Expression by Phosphatidylinositol 3-Kinase/Akt Downstream Substrate, FOXO3a, and Their Roles in Apoptosis of LNCaP Prostate Cancer Cells

Yang, L., Xie, S., Jamaluddin, M. S., Altuwaijri, S., Ni, J., Kim, E., Chen, Y.-T., Hu, Y.-C., Wang, L., Chuang, K.-H., et al. (2005) · Journal of Biological Chemistry

FOXO transcription factor regulationProstate Cancer Treatment and Research

Cited by 131